Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Kevin Holme"'
Autor:
Siegfried H. Reich, Stephen K. Burley, Spencer Emtage, Stephen R. Wasserman, Kevin Holme, Shane Atwell, Laura A. Pelletier, Lydia Smyth, Devon A. Thompson, Paul A. Sprengeler, Jeff M. Blaney, Tuan H. Do, Barbara C. Leon, Jason Adams, Isabelle A. Rooney, Marijane Russell, Kenneth D. Schwinn, J. Michael Sauder, Steve F. Gessert, Brandon E. Aubol, Marshall C. Peterman, Karen J. Froning, Jeremy D. Felce, Nanni H. Huser, Crystal M. Tang, Katti A. Jessen, Pierre-Yves Bounaud, Christopher R. Smith, Patrick S. Lee, Jorg Hendle, Sean G. Buchanan
Supplementary Tables 1-3, Figures 1-4 from SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b253da2b8af69b57f61a86d3221a13f9
https://doi.org/10.1158/1535-7163.22485138
https://doi.org/10.1158/1535-7163.22485138
Autor:
Siegfried H. Reich, Stephen K. Burley, Spencer Emtage, Stephen R. Wasserman, Kevin Holme, Shane Atwell, Laura A. Pelletier, Lydia Smyth, Devon A. Thompson, Paul A. Sprengeler, Jeff M. Blaney, Tuan H. Do, Barbara C. Leon, Jason Adams, Isabelle A. Rooney, Marijane Russell, Kenneth D. Schwinn, J. Michael Sauder, Steve F. Gessert, Brandon E. Aubol, Marshall C. Peterman, Karen J. Froning, Jeremy D. Felce, Nanni H. Huser, Crystal M. Tang, Katti A. Jessen, Pierre-Yves Bounaud, Christopher R. Smith, Patrick S. Lee, Jorg Hendle, Sean G. Buchanan
Supplementary Figure 1 from SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee53a296e3d5b8a6d460e10e97860b5a
https://doi.org/10.1158/1535-7163.22485141.v1
https://doi.org/10.1158/1535-7163.22485141.v1
Autor:
Siegfried H. Reich, Stephen K. Burley, Spencer Emtage, Stephen R. Wasserman, Kevin Holme, Shane Atwell, Laura A. Pelletier, Lydia Smyth, Devon A. Thompson, Paul A. Sprengeler, Jeff M. Blaney, Tuan H. Do, Barbara C. Leon, Jason Adams, Isabelle A. Rooney, Marijane Russell, Kenneth D. Schwinn, J. Michael Sauder, Steve F. Gessert, Brandon E. Aubol, Marshall C. Peterman, Karen J. Froning, Jeremy D. Felce, Nanni H. Huser, Crystal M. Tang, Katti A. Jessen, Pierre-Yves Bounaud, Christopher R. Smith, Patrick S. Lee, Jorg Hendle, Sean G. Buchanan
The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics. Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers. In other cancers, such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::265be7461b5631c4751aa9dac9de05d6
https://doi.org/10.1158/1535-7163.c.6531795.v1
https://doi.org/10.1158/1535-7163.c.6531795.v1
Autor:
George M. Grass, Jesus Castelo, Kyoung-Jin Lee, Nikole Johnson, Patrick J. Sinko, Yong-Hee Lee, Kevin Holme
Publikováno v:
European Journal of Pharmaceutical Sciences. 25:193-200
The effect of experimental (apical) pH on absorptive permeability (Pe) was investigated in animal intestinal tissues and Caco-2 cell monolayers to examine whether the introduction of physiological pH such as 6.5 relates to the better prediction of an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d8f6190ed8c388cce891d308eb581de
https://doi.org/10.1016/j.ejps.2005.02.012
https://doi.org/10.1016/j.ejps.2005.02.012
Autor:
Rachel Mower, Patrick J. Sinko, Kevin Holme, Perry Gordon, Kyoung-Jin Lee, Jesus Castelo, Yong-Hee Lee, Nikole Johnson, Tom Hollenbeck
Publikováno v:
Pharmaceutical Research. 20:1015-1021
Purpose. The aim of this study was to reduce or prevent nonspecific binding (NSB) of compounds to ultrafiltration (UF) protein binding (PB) testing units. Methods. UF units (regenerated cellulose, MWCO 10K) were used for PB and NSB measurements with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b615f82cc5bad03e67eab58ecaa2940
https://doi.org/10.1023/a:1024406221962
https://doi.org/10.1023/a:1024406221962
Autor:
Daniel E. Levy, France Lapierre, Weisheng Liang, Wenqing Ye, Christopher W. Lange, Xiaoyuan Li, Damian Grobelny, Marie Casabonne, David Tyrrell, Kevin Holme, Alex Nadzan, Richard E. Galardy
Publikováno v:
Journal of Medicinal Chemistry. 41:199-223
Modifications around the dipeptide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied. These variations incorporated a variety of natural, unnatural, and synthetic amino acids in addition to modifications of the P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3305083e8dd9cc67803fbd243001f88
https://doi.org/10.1021/jm970494j
https://doi.org/10.1021/jm970494j
Autor:
Jeff Blaney, Pierre-Yves Bounaud, Sean Buchanan, Barbara C. Leon, Laura A. Pelletier, Kenneth D. Schwinn, Kevin Holme, Jorg Hendle, S. Emtage, Marshall C. Peterman, Shane Atwell, Paul A. Sprengeler, Patrick Lee, Crystal Tang, Tuan H. Do, Katti A. Jessen, Siegfried H. Reich, Brandon E. Aubol, Isabelle Rooney, Marijane Russell, Nanni Huser, D.A. Thompson, Steve F. Gessert, Lydia Smyth, Jeremy Felce, J. Michael Sauder, Christopher Ronald Smith, Jason Adams, S.R. Wasserman, Stephen K. Burley, Karen Froning
Publikováno v:
Molecular cancer therapeutics. 8(12)
The MET receptor tyrosine kinase has emerged as an important target for the development of novel cancer therapeutics. Activation of MET by mutation or gene amplification has been linked to kidney, gastric, and lung cancers. In other cancers, such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c26c5358efb0d1522269f925d044537
https://pubmed.ncbi.nlm.nih.gov/19934279
https://pubmed.ncbi.nlm.nih.gov/19934279
Autor:
Michael W. Deininger, Jeffrey W. Tyner, Stephen K. Burley, Crystal Tang, Sean Buchanan, Amie S. Corbin, Hal A. Lewis, Katayoun Jessen, Richard Romero, Christopher A. Eide, Matthew J. Wong, Thomas O'Hare, Kevin Holme
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 105(14)
Imatinib inhibits Bcr-Abl, the oncogenic tyrosine kinase that causes chronic myeloid leukemia. The second-line inhibitors nilotinib and dasatinib are effective in patients with imatinib resistance resulting from Bcr-Abl kinase domain mutations. Bcr-A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::626ad44327a51b8534531da70042bc84
https://pubmed.ncbi.nlm.nih.gov/18367669
https://pubmed.ncbi.nlm.nih.gov/18367669
Publikováno v:
Journal of Applied Corporate Finance. 3:56-64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1c0f427b8b9a99835ef7d50d9fcf12f
https://doi.org/10.1111/j.1745-6622.1990.tb00195.x
https://doi.org/10.1111/j.1745-6622.1990.tb00195.x
Autor:
Kyoung-Jin, Lee, Rachel, Mower, Tom, Hollenbeck, Jesus, Castelo, Nikole, Johnson, Perry, Gordon, Patrick J, Sinko, Kevin, Holme, Yong-Hee, Lee
Publikováno v:
Pharmaceutical research. 20(7)
The aim of this study was to reduce or prevent nonspecific binding (NSB) of compounds to ultrafiltration (UF) protein binding (PB) testing units.UF units (regenerated cellulose, MWCO 10K) were used for PB and NSB measurements with or without pretreat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::57c8e86e3880057200a5362c647dfb66
https://pubmed.ncbi.nlm.nih.gov/12880287
https://pubmed.ncbi.nlm.nih.gov/12880287